NS

Namrata Suhas Mundhe

Active Director Additional Director DIN 11000289
DIN 11000289 First appointment Feb 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Namrata Suhas Mundhe

Data last updated:

Namrata Suhas Mundhe is an Additional Director at Cliquemed Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11000289
Primary Designation Additional Director
Industry Pharma
First Appointment 28 Feb 2025
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Additional Director28 Feb 20252024Active

Directorship timeline

Open interactive timeline →
Cliquemed Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Namrata Suhas Mundhe

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Namrata Suhas Mundhe

Namrata Suhas Mundhe currently holds 1 directorship: Cliquemed Pharmaceuticals Private Limited (Additional Director, since 28 Feb 2025).

Namrata Suhas Mundhe was first appointed on 28 Feb 2025 as Additional Director at Cliquemed Pharmaceuticals Private Limited.

The current boards of Namrata Suhas Mundhe's companies include Smita Ravindra Kadav (Cliquemed Pharmaceuticals Private Limited), Sunita Pratapsinh Nangare (Cliquemed Pharmaceuticals Private Limited), Sushma Sandesh Kamble (Cliquemed Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available